An observational study in Tumor of Lung and Pulmonary Nodule, sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.
Among the 850 studies in Lung Neoplasms with a site in China, this one is the 153rd largest by planned enrollment of the 259 observational ones that give a count, is one of 113 that started in 2024, is one of 259 observational ones, reaches primary completion later than 56 of the 422 other live ones, and was the 566th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–80
Xiamen University · Sites in China
Ages 18–80
AstraZeneca · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 15 Years to 75 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 226 · Phase 3 77 · Phase 4 9
First in 1992; this study’s year is marked. 113 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 90 across the 590 interventional studies, 307 across the 259 observational. Of the 208 that completed or were terminated, 36 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 850 have an industry lead sponsor. The 10 most frequent:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University has 4 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
118 of the studies in Lung Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607796Phase 3Zhou ChengzhiEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04841811Phase 3Guangdong Association of Clinical TrialsMDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | 2026-12-31 |
| NCT06598527Phase 3Yang HongStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study | 2027-01-30 |
Add all 118 to your calendar (.ics) → With an account.
Among the 850 studies in Lung Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on previous studies, this project intends to use prospective studies to select patients identified by imaging as pulmonary nodules to explore the potential of RP5-977B1 in differentiating benign and malignant pulmonary nodules, construct diagnostic models combined with clinical protein tumor markers, compare the diagnostic efficacy of the two, and finally determine the sensitivity and specificity of markers through pathological results. It provides a new content for the diagnosis of benign and malignant pulmonary nodules.
For the purpose of clinical diagnosis, disease monitoring, treatment or prognosis assessment, patients with pulmonary nodules may need to draw blood for routine laboratory tests several times during diagnosis and treatment. There may be some blood samples to be discarded after the completion of routine tests. This clinical trial will only use these remaining blood samples as research samples. The samples collected in this part of the study were serum samples from patients with pulmonary nodules, and 50 subjects were planned to be enrolled.
Admission criteria: ① Pulmonary nodules were detected by imaging and surgically resected.
② Age 15-75 years old.
Surgery or puncture is to be performed for pathological diagnosis.
Exclusion criteria: ① Patient samples have hemolysis, have been contaminated, have been placed for too long, have insufficient sample allowance, and have mixed records.
History of malignant tumor.
Serious underlying diseases and complications may affect systemic treatment. ④ Can not guarantee to receive blood tests on time.
Exclusion criteria: ① Subjects who do not meet the inclusion criteria or who meet the exclusion criteria and are mistakenly enrolled.
Samples collected for two or more times from the same patient should be retained only the samples collected for the first time, and all subsequent samples collected should be excluded.
Samples with incomplete case information. ④ Sample quality control unqualified samples due to sample collection, storage, transportation and other reasons.
Serum samples from patients with radiographic findings and surgical removal of pulmonary nodules were selected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pulmonary nodules were detected by imaging and surgically resected.
Age 15-75 years old.
Surgery or puncture is to be performed for pathological diagnosis.
Exclusion Criteria:
Patient samples have hemolysis, have been contaminated, have been placed for too long, have insufficient sample allowance, and record mixed samples.
* Pulmonary nodules were detected by imaging and surgically resected. * Age 15-75 years old. * Surgery or puncture is to be performed for pathological diagnosis. ④ Adequate hematological function and liver and kidney function reserve. ⑤ The sample has no hemolysis, sufficient margin, and the source record is clear and can be checked.
* Pulmonary nodules were detected by imaging and surgically resected. * Age 15-75 years old. * Surgery or puncture is to be performed for pathological diagnosis. ④ Adequate hematological function and liver and kidney function reserve. ⑤ The sample has no hemolysis, sufficient margin, and the source record is clear and can be checked.
Benign nodule
Pathological findings determined that the nodules were benign in the patient
Time frame: A week
Tumor
Pathological findings identified the nodules as malignant tumors in the patient
Time frame: A week
Plan to share: No — Due to the requirements of the institution and the need to protect the privacy of patients, it is not convenient to disclose IPD.
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 12 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University